{"id":57629,"date":"2024-02-27T17:53:24","date_gmt":"2024-02-27T17:53:24","guid":{"rendered":"https:\/\/medsname.com\/veenat\/"},"modified":"2026-04-30T10:24:24","modified_gmt":"2026-04-30T10:24:24","slug":"veenat","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/veenat\/","title":{"rendered":"Veenat"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns Rapid \u2014 Ce este Veenat?<\/h3>\n<p style=\"margin:0;\"><strong>Veenat<\/strong> este un comprimat oral de la Natco Pharma care con\u021bine <strong>imatinib mesilat<\/strong> la <strong>100 mg<\/strong> \u2014 originalul <strong>inhibitor al tirosin-cinazei BCR-ABL<\/strong> \u0219i medicamentul care a transformat leucemia mieloid\u0103 cronic\u0103 (LMC) dintr-o boal\u0103 fatal\u0103 \u00eentr-o afec\u021biune cronic\u0103. Indica\u021bii standard: <strong>LMC \u00een faz\u0103 cronic\u0103<\/strong> (400 mg\/zi), <strong>LMC \u00een faz\u0103 accelerat\u0103\/blastic\u0103<\/strong> (600\u2013800 mg\/zi), <strong>LLA pozitiv\u0103 pentru cromozomul Philadelphia<\/strong>, <strong>tumoral stromal gastrointestinal (GIST)<\/strong>, \u0219i alte c\u00e2teva tipuri rare de cancer determinate de KIT\/PDGFRA. <strong>Administra\u021bi \u00een timpul mesei \u0219i cu un pahar mare de ap\u0103<\/strong> pentru a reduce tulbur\u0103rile gastrointestinale. Monitorizare obligatorie: hemoleucogram\u0103 + teste hepatice la fiecare 2 s\u0103pt\u0103m\u00e2ni \u00een primele 2\u20133 luni, apoi lunar; r\u0103spuns citogenetic + molecular (transcript BCR-ABL) la fiecare 3 luni \u00een LMC.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Supraveghere specializat\u0103 necesar\u0103.<\/strong> Medicamentele pentru cancer trebuie prescrise de un oncolog tratant, cu un diagnostic confirmat, stadializare ini\u021bial\u0103 \u0219i un plan de tratament definit. Nu \u00eencepe\u021bi, nu opri\u021bi, nu modifica\u021bi doza \u0219i nu utiliza\u021bi medicamente pentru cancer \u00een afara unui plan de \u00eengrijire condus de oncologie. Majoritatea medicamentelor pentru cancer necesit\u0103 monitorizare regulat\u0103 prin analize de s\u00e2nge (hemoleucogram\u0103, teste hepatice, func\u021bie renal\u0103), sunt absolut contraindicate \u00een sarcin\u0103 \u0219i au interac\u021biuni medicamentoase semnificative.<\/div>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 Checkout criptat<\/strong> \u00b7 <strong>\ud83d\udcb3 Procesor verificat<\/strong> \u00b7 <strong>\ud83d\ude9a Livrare worldwide<\/strong> \u00b7 <strong>\u2b50 4,9\/5 de la peste 1.400 de clien\u021bi<\/strong>\n<\/div>\n<h2 class=\"wp-block-heading\">Ce este Veenat?<\/h2>\n<p>Veenat este un comprimat oral de la Natco Pharma care con\u021bine <strong>imatinib mesilat 100 mg<\/strong>. Imatinib a fost primul inhibitor selectiv <strong>inhibitor al tirosin-cinazei BCR-ABL<\/strong> aprobat (Novartis, denumire comercial\u0103 Gleevec\/Glivec, 2001) \u0219i a revolu\u021bionat tratamentul leucemiei mieloide cronice (LMC) \u2014 transform\u00e2nd o boal\u0103 anterior fatal\u0103 \u00eentr-o afec\u021biune cronic\u0103 cu speran\u021b\u0103 de via\u021b\u0103 aproape normal\u0103 sub tratament. Blocheaz\u0103 \u0219i kinazele receptor KIT \u0219i PDGFRA \u00eenrudite, fiind activ \u00een tumoare stromal\u0103 gastrointestinal\u0103 (GIST) \u0219i \u00een alte tipuri rare de cancer.<\/p>\n<h2 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103 Veenat?<\/h2>\n<p>Cromozomul Philadelphia (o transloca\u021bie t(9;22)) creeaz\u0103 kinaza de fuziune <strong>BCR-ABL constitutiv activ\u0103<\/strong> care determin\u0103 leucemia mieloid\u0103 cronic\u0103. Imatinib se leag\u0103 de situl de legare al ATP al BCR-ABL \u0219i \u00eel blocheaz\u0103 \u00eentr-o conforma\u021bie inactiv\u0103, oprind semnalul proliferativ. Acela\u0219i compus inhib\u0103 \u0219i receptorul KIT \u00eenrudit (supraactiv \u00een GIST \u0219i mastocitoz\u0103) \u0219i receptorul PDGFRA (supraactiv \u00een unele sarcome).<\/p>\n<h2 class=\"wp-block-heading\">Utiliz\u0103ri \u0219i indica\u021bii<\/h2>\n<ul>\n<li><strong>LMC pozitiv\u0103 pentru cromozomul Philadelphia \u00een faz\u0103 cronic\u0103<\/strong> (prim\u0103 linie; 400 mg\/zi)<\/li>\n<li><strong>LMC \u00een faz\u0103 accelerat\u0103 sau de criza blastelor<\/strong> (600\u2013800 mg\/zi, adesea ca punte c\u0103tre transplant alogen)<\/li>\n<li><strong>Leucemia acut\u0103 limfoblastic\u0103 (LAL) pozitiv\u0103 pentru cromozomul Philadelphia<\/strong>, \u00een combina\u021bie cu chimioterapia<\/li>\n<li><strong>Tumoral stromal\u0103 gastrointestinal\u0103 (GIST) nerezectabil\u0103, recurent\u0103 sau metastatic\u0103<\/strong><\/li>\n<li><strong>Terapie adjuvant\u0103 dup\u0103 rezec\u021bia GIST<\/strong> (3 ani, boal\u0103 KIT-pozitiv\u0103)<\/li>\n<li><strong>Sindrom hiperozinofilic cu fuziune FIP1L1-PDGFRA<\/strong><\/li>\n<li><strong>Dermatofibrosarcom protuberans<\/strong> (determinat de PDGFRB)<\/li>\n<li><strong>Mastocitoz\u0103 sistemic\u0103 agresiv\u0103<\/strong> (KIT D816V negativ)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Dozarea Veenat \u0219i cum s\u0103 o lua\u021bi<\/h2>\n<p>Doze standard pe indica\u021bie:<\/p>\n<ul>\n<li>LMC \u00een faz\u0103 cronic\u0103: <strong>400 mg\/zi<\/strong> (1 comprimat de 400 mg)<\/li>\n<li>LMC accelerat\u0103\/blast, LLA Ph+: <strong>600\u2013800 mg\/zi<\/strong> (\u00een 1\u20132 doze divizate)<\/li>\n<li>GIST: <strong>400 mg\/zi<\/strong>; cre\u0219te\u021bi la 800 mg\/zi \u00een caz de progresie<\/li>\n<\/ul>\n<ol>\n<li><strong>Administra\u021bi \u00een timpul mesei \u0219i cu un pahar mare de ap\u0103<\/strong> \u2014 minimizeaz\u0103 grea\u021ba \u0219i irita\u021bia esofagian\u0103.<\/li>\n<li><strong>Aceea\u0219i or\u0103 \u00een fiecare zi.<\/strong><\/li>\n<li><strong>\u00cenghi\u021bi\u021bi \u00eentreg.<\/strong> Comprimatele pot fi dispersate \u00een ap\u0103 sau suc de mere (nu suc de grapefruit) dac\u0103 \u00eenghi\u021birea este dificil\u0103.<\/li>\n<li><strong>Monitorizare obligatorie:<\/strong> Hemogram\u0103 + teste hepatice la fiecare 2 s\u0103pt\u0103m\u00e2ni pentru primele 2\u20133 luni, apoi lunar. Nivelul transcritului BCR-ABL (PCR) la fiecare 3 luni \u00een LMC \u2014 m\u0103sur\u0103 cheie a r\u0103spunsului la tratament. ECG\/ecocardiografie anual\u0103 pentru func\u021bia cardiac\u0103.<\/li>\n<li><strong>R\u0103spuns medular + citogenetic:<\/strong> la baz\u0103 \u0219i la 3, 6, 12 luni \u00een LMC \u2014 define\u0219te succesul tratamentului sau necesitatea trecerii la TKI de linia a doua (dasatinib, nilotinib, bosutinib, ponatinib).<\/li>\n<li><strong>Nu \u00eentrerupe\u021bi f\u0103r\u0103 instruc\u021biuni oncologului.<\/strong> \u2014 remisia f\u0103r\u0103 tratament este posibil\u0103 doar dup\u0103 un r\u0103spuns molecular profund sus\u021binut (MR4 sau mai bun) timp de minimum 2 ani, sub supraveghere specializat\u0103.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Efecte secundare ale Veenat<\/h2>\n<p><strong>Frecvente (adesea u\u0219oare, temporare):<\/strong> gre\u021buri, diaree, reten\u021bie de lichide (edem periorbital, edem periferic), crampe musculare, erup\u021bii cutanate, oboseal\u0103, cre\u0219tere \u00een greutate.<\/p>\n<p><strong>Important \u2014 monitorizare obligatorie:<\/strong><\/p>\n<ul>\n<li><strong>Mielosupresie<\/strong> \u2014 neutropenie, trombocitopenie, anemie (foarte frecvente); reducerea dozei sau \u00eentrerupere pentru forme severe<\/li>\n<li><strong>Hepatotoxicitate<\/strong> \u2014 cre\u0219teri enzimatice hepatice frecvente; se poate produce hepatit\u0103 sever\u0103<\/li>\n<li>Disfunc\u021bie cardiac\u0103 \u2014 insuficien\u021b\u0103 cardiac\u0103 congestiv\u0103 (rar\u0103 dar documentat\u0103)<\/li>\n<li>Hipotiroidism la pacien\u021bii post-tiroidectomie sub tratament cu levotiroxin\u0103<\/li>\n<li>Hipofosfatemie, hipocalcemie<\/li>\n<li>Disfunc\u021bie renal\u0103<\/li>\n<\/ul>\n<p><strong>Rare dar grave:<\/strong> Sindrom Stevens-Johnson \/ TEN, insuficien\u021b\u0103 hepatic\u0103, reten\u021bie sever\u0103 de lichide, hemoragie gastrointestinal\u0103, sindrom de liz\u0103 tumoral\u0103 (\u00eenc\u0103rc\u0103tur\u0103 tumoral\u0103 mare), edem cerebral la pacien\u021bi cu metastaze cerebrale.<\/p>\n<h2 class=\"wp-block-heading\">Avertismente \u0219i precau\u021bii<\/h2>\n<ul>\n<li><strong>Sarcina:<\/strong> teratogen \u00een studii pe animale; raport\u0103ri de cazuri de malforma\u021bii umane. Contraceptie eficient\u0103 pe durata tratamentului \u0219i 14 zile dup\u0103 ultima doz\u0103. Discuta\u021bi cu oncologul dac\u0103 planifica\u021bi sarcin\u0103.<\/li>\n<li><strong>Al\u0103ptarea:<\/strong> evita\u021bi \u2014 imatinib excretat \u00een laptele matern.<\/li>\n<li><strong>Istoric de disfunc\u021bie cardiac\u0103:<\/strong> monitorizare de baz\u0103 + monitorizare continu\u0103 prin ecografie\/BNP.<\/li>\n<li><strong>Boal\u0103 hepatic\u0103:<\/strong> dozare prudent\u0103; monitoriza\u021bi testele hepatice s\u0103pt\u0103m\u00e2nal la \u00eenceput.<\/li>\n<li><strong>Hipotiroidism tratat cu levotiroxin\u0103:<\/strong> imatinibul cre\u0219te clearance-ul levotiroxinei; verifica\u021bi TSH \u0219i ajusta\u021bi doza de levotiroxin\u0103 dup\u0103 necesit\u0103\u021bi.<\/li>\n<li><strong>Interven\u021bie chirurgical\u0103:<\/strong> risc crescut de s\u00e2ngerare din cauza vindec\u0103rii deficiente a r\u0103nilor; \u00eentrerupe\u021bi imatinibul perioperator sub \u00eendrumare specializat\u0103.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Combina\u021bi cu<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Efect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Ce s\u0103 face\u021bi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inhibitori puternici ai CYP3A4 (ketoconazol, ritonavir, claritromicin\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cre\u0219terea nivelului de imatinib \u2014 toxicitate<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce\u021bi doza de imatinib cu ~50% dac\u0103 este inevitabil.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inductori puternici ai CYP3A4 (rifampicin\u0103, fenitoin\u0103, carbamazepin\u0103, Hypericum perforatum)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Sc\u0103derea nivelului de imatinib \u2014 e\u0219ec terapeutic<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi. Dac\u0103 este inevitabil, cre\u0219te\u021bi doza cu 50% sub \u00eendrumare specializat\u0103.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Risc crescut de s\u00e2ngerare (inhibi\u021bie CYP2C9 + efecte pe plachete)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Comuta\u021bi la HBPM sau DOAC; monitoriza\u021bi INR s\u0103pt\u0103m\u00e2nal la \u00eenceput.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Levotiroxin\u0103<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Imatinibul cre\u0219te clearance-ul levotiroxinei \u2014 cre\u0219terea TSH<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitoriza\u021bi TSH; ajusta\u021bi doza de levotiroxin\u0103 dup\u0103 necesit\u0103\u021bi.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Paracetamol (doze mari, administrare regulat\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Hepatotoxicitate cumulativ\u0103<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Limita\u021bi la utilizare ocazional\u0103.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Suc de grapefruit<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cre\u0219te nivelurile de imatinib<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi grapefruit \u0219i sucul de grapefruit.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<ul>\n<li>P\u0103stra\u021bi la temperatur\u0103 ambiant\u0103, 15\u201330\u00b0C, \u00een blisterul original.<\/li>\n<li>P\u0103stra\u021bi la distan\u021b\u0103 de copii, femei \u00een v\u00e2rst\u0103 fertil\u0103 \u0219i animale de companie.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Alternative conexe pe MedsBase<\/h2>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/imat\/\"><strong>Imat (imatinib 400 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/imatib\/\"><strong>Imatib (imatinib 100 \/ 400 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/votrient\/\"><strong>Votrient (pazopanib 400 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/ro\/anti-cancer-medication\/\">R\u0103sfoi\u021bi toate medicamentele anti-cancer \u2192<\/a><\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">C\u00e2t de eficient este Veenat pentru leucemia mieloid\u0103 cronic\u0103?<\/h3>\n<p>Imatinibul este una dintre cele mai de succes terapii \u021bintite \u00eempotriva cancerului dezvoltate vreodat\u0103. <strong>Supravie\u021buirea global\u0103 la 10 ani \u00een CML \u00een faz\u0103 cronic\u0103 sub tratament cu imatinib este de aproximativ 85%<\/strong>, comparativ cu o supravie\u021buire median\u0103 de 4\u20136 ani \u00eenaintea terapiei cu TKI. Aproximativ 90% dintre pacien\u021bi ob\u021bin un r\u0103spuns citogenetic complet \u00een 12\u201318 luni. O minoritate semnificativ\u0103 (~50% cu r\u0103spuns molecular profund sus\u021binut) poate \u00eencerca \u00een cele din urm\u0103 remisiune f\u0103r\u0103 tratament sub supraveghere specializat\u0103.<\/p>\n<h3 class=\"wp-block-heading\">De ce trebuie s\u0103 iau Veenat cu m\u00e2ncare?<\/h3>\n<p>Dou\u0103 motive: (1) alimenta\u021bia reduce semnificativ greata \u0219i riscul de irita\u021bie esofagian\u0103; (2) imatinibul are o absorb\u021bie oral\u0103 bun\u0103 \u00een orice caz, dar administrarea constant\u0103 cu m\u00e2ncare reduce variabilitatea zilnic\u0103. Lua\u021bi-l cu cea mai mare mas\u0103 a zilei \u0219i un pahar plin de ap\u0103. Evita\u021bi administrarea pe stomacul gol sau cu suc de grapefruit (care cre\u0219te nivelurile \u0219i riscul de toxicitate).<\/p>\n<h3 class=\"wp-block-heading\">Ce analize de s\u00e2nge am nevoie?<\/h3>\n<p><strong>Obligatoriu:<\/strong> Hemogram\u0103 \u0219i teste hepatice la fiecare 2 s\u0103pt\u0103m\u00e2ni pentru primele 2\u20133 luni, apoi lunar. <strong>Nivelul transcritului BCR-ABL prin PCR la fiecare 3 luni<\/strong> \u00een CML \u2014 aceasta este m\u0103sura cheie a r\u0103spunsului la tratament \u0219i decide continuarea imatinibului sau trecerea la un TKI de genera\u021bia a doua (dasatinib, nilotinib). Evaluarea cardiac\u0103 anual\u0103 (ECG, ecocardiografie sau BNP) este rezonabil\u0103 la pacien\u021bii cu factori de risc cardiac.<\/p>\n<h3 class=\"wp-block-heading\">Pot avea copii \u00een timp ce iau Veenat?<\/h3>\n<p>Imatinibul este teratogen \u00een studiile pe animale \u0219i exist\u0103 rapoarte de cazuri de malforma\u021bii umane. <strong>Contracep\u021bia puternic\u0103 este obligatorie pe tot parcursul tratamentului \u0219i pentru cel pu\u021bin 14 zile dup\u0103 ultima doz\u0103<\/strong>, at\u00e2t la pacien\u021bii de sex masculin, c\u00e2t \u0219i feminin. Discuta\u021bi planificarea familiei cu oncologul \u00eenainte de a \u00eencepe tratamentul \u2014 \u00een unele cazuri, o \u00eencercare planificat\u0103 de remisiune f\u0103r\u0103 tratament poate crea o fereastr\u0103 pentru concep\u021bie.<\/p>\n<h3 class=\"wp-block-heading\">Ce \u00eenseamn\u0103 \u201cremisiune f\u0103r\u0103 tratament\u201d \u00een CML?<\/h3>\n<p>Aproximativ 50% dintre pacien\u021bii cu LMC care ating un r\u0103spuns molecular sus\u021binut <strong>profund (MR4 sau mai bun) timp de cel pu\u021bin 2\u20133 ani<\/strong> pot \u00eencerca s\u0103 \u00eentrerup\u0103 imatinibul sub monitorizare atent\u0103. Aproximativ jum\u0103tate dintre cei care \u00eentrerup men\u021bin remisiunea f\u0103r\u0103 tratament pe termen nelimitat. Cealalt\u0103 jum\u0103tate recidiveaz\u0103 molecular \u0219i re\u00eencepe imatinibul (care de obicei reinduce remisiunea). Aceasta este o decizie specializat\u0103 \u2014 nu \u00eentrerupe\u021bi niciodat\u0103 imatinibul unilateral.<\/p>\n<h3 class=\"wp-block-heading\">Veenat vs noi inhibitori de tirosin-kinaz\u0103 (dasatinib, nilotinib, bosutinib)?<\/h3>\n<p>Imatinibul este de prim\u0103 linie pentru majoritatea pacien\u021bilor cu LMC \u00een faz\u0103 cronic\u0103 recent diagnostica\u021bi \u2014 istoric lung de siguran\u021b\u0103, cost mai mic, date stabilite privind remisiunea f\u0103r\u0103 tratament. <strong>Dasatinibul \u0219i nilotinibul<\/strong> sunt TKI-uri de genera\u021bia a doua cu r\u0103spunsuri moleculare mai rapide \u0219i mai profunde; preferate ca prim\u0103 linie \u00een cazuri cu risc mai ridicat sau la pacien\u021bii mai tineri care prioritizeaz\u0103 remisiunea f\u0103r\u0103 tratament. <strong>Bosutinibul, ponatinibul<\/strong> sunt rezervate pentru rezisten\u021b\u0103 sau intoleran\u021b\u0103. Alegerea este foarte individual\u0103 \u2014 decizie de hematologie specializat\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Va func\u021biona Veenat pentru tumoarea mea GIST?<\/h3>\n<p>Pentru GIST, r\u0103spunsul la imatinib depinde de muta\u021bia KIT sau PDGFRA subiacent\u0103. <strong>Muta\u021biile KIT exon 11<\/strong> au o rat\u0103 de r\u0103spuns par\u021bial de ~85% la 400 mg\/zi. <strong>Muta\u021biile KIT exon 9<\/strong> necesit\u0103 800 mg\/zi. <strong>KIT\/PDGFRA wild-type GIST \u0219i muta\u021bia PDGFRA D842V<\/strong> r\u0103spund slab \u2014 sunt necesare TKI alternative (avapritinib pentru D842V). Testarea muta\u021bional\u0103 este obligatorie \u00eenainte de a \u00eencepe tratamentul cu imatinib pentru GIST.<\/p>\n<h3 class=\"wp-block-heading\">De ce re\u021bin lichide \u00een timp ce iau Veenat?<\/h3>\n<p>Reten\u021bia de lichide \u2014 umfl\u0103turi periorbitare, umfl\u0103turi la glezne, cre\u0219tere \u00een greutate \u2014 este unul dintre cele mai distinctive efecte adverse ale imatinibului, afect\u00e2nd p\u00e2n\u0103 la 60% din pacien\u021bi. Mecanismul implic\u0103 inhibarea PDGFR \u0219i o u\u0219oar\u0103 reten\u021bie renal\u0103 de sodiu. Se poate gestiona cu o diet\u0103 s\u0103rac\u0103 \u00een sare \u0219i, dac\u0103 este necesar, cu diuretice moderate. Reten\u021bia sever\u0103 de lichide (edem pulmonar, efuziune pleural\u0103) necesit\u0103 reducerea dozei sau \u00eentreruperea tratamentului.<\/p>\n<h3 class=\"wp-block-heading\">Pot consuma alcool \u00een timp ce iau Veenat?<\/h3>\n<p>Limita\u021bi consumul de alcool \u2014 at\u00e2t alcoolul, c\u00e2t \u0219i imatinibul sunt metaboliza\u021bi de ficat, iar combina\u021bia cre\u0219te riscul de hepatotoxicitate. Cantit\u0103\u021bi mici ocazionale sunt de obicei tolerabile; consumul zilnic sau excesiv ar trebui evitat. Anun\u021ba\u021bi oncologul dac\u0103 valorile testelor hepatice (LFTs) cresc.<\/p>\n<p><!-- medsbase-why-order --><\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Fiecare lot este procurat de la un <strong>produc\u0103tor certificat WHO-GMP<\/strong>. Comenzile sunt expediate \u00een ambalaje simple, f\u0103r\u0103 marc\u0103, de la partenerii no\u0219tri de onorare \u0219i acoperite de <a href=\"\/ro\/medsbase-re-shipment-assurance-policy\/\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>: dac\u0103 un colet nu ajunge \u00een 20 de zile lucr\u0103toare, trimitem gratuit o nou\u0103 comand\u0103, f\u0103r\u0103 \u00eentreb\u0103ri.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Medicamente Anticanceroase Asem\u0103n\u0103toare<\/h3>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/imat\/\">Imat (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/imatib\/\">Imatib (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/votrient\/\">Votrient (pazopanib 200\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/hydrosar\/\">Hydrosar (hidroxiuree 500 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/riborea\/\">Riborea (ribociclib 200 mg)<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Trateaz\u0103 leucemia<br \/>\n\u2705 Gestioneaz\u0103 tumori stromale gastrointestinale<br \/>\n\u2705 Inhib\u0103 cre\u0219terea celulelor canceroase<br \/>\n\u2705 Cre\u0219te ratele de supravie\u021buire<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te calitatea vie\u021bii<\/p>\n<p>Veenat con\u021bine Imatinib.<\/p>","protected":false},"featured_media":57630,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[4330,4338],"class_list":{"0":"post-57629","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_tag-imatinib","10":"product_tag-veenat","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/57629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=57629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/57630"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=57629"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=57629"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=57629"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=57629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}